SimonMed is creating the first fully automated AI-powered lung cancer risk assessment workflow deployed at enterprise scale, combining multiple FDA-cleared AI technologies into a...

Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS® platform

Optellum announced it has been awarded funding for a competitive programme, Invention for Innovation (i4i), focused on transformative and disruptive innovations to reduce waiting...

Tanner Health and Healthliant Ventures announce the launch of Optellum’s Virtual Nodule Clinic® (VNC), an artificial intelligence (AI) platform designed to assist care teams...

OXFORD, United Kingdom and HOUSTON, United States, June 4, 2026 - Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical...

Massive Bio and Optellum today announced a collaboration to bridge early lung cancer detection with clinical trial access for patients with non-small cell lung...

First lifetime payer-perspective economic analysis of AI-assisted risk stratification for indeterminate pulmonary nodules (IPN).

Optellum is thrilled to announce that it has received Therapeutic Goods Administration (TGA) class IIb approval in Australia for Virtual Nodule Clinic (VNC) platform...

Optellum is pleased to announce its selection in a landmark NHS initiative...

Optellum announced the closure of its Series B funding round. The round included new investment from Woori Venture Partners, the venture arm of Woori...

Optellum announced new clinical evidence demonstrating the impact of its Virtual Nodule Clinic (VNC) with Lung Cancer Prediction (LCP) AI...

Optellum announced the world’s first thorax CT foundation model built for precision lung care in real-world settings – an ambitious initiative aiming to revolutionize...

As leaders in AI-driven lung cancer diagnostics, we’re committed to advancing the field of interventional pulmonology and supporting the clinicians, researchers, and innovators driving it forward....

Participant information Optellum is an innovative MedTech company that has developed FDA and CE/UKCA-approved clinical decision support software for lung cancer diagnosis. Our artificial...

Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has entered an agreement with Bristol Myers Squibb (NYSE: BMY),...

Optellum, the leader in AI-enabled lung cancer diagnosis, today announced it has entered a strategic agreement with Volpara Health, a Lunit company and a...

Our mission is to catch lung cancer earlier, drive a stage shift, and ultimately improve patient outcomes. This is why we're proud to announce...

We're excited to see how technology is transforming patient care across North Carolina, as highlighted in this recent article featuring Optellum Virtual Nodule Clinic.

We are thrilled to share a recent article and TV news segment from UConn Today highlighting the significant strides UConn Health has made in...

OXFORD, UK 12 Nov 2024: Optellum®, a leading innovator in artificial intelligence (AI) and medical imaging for lung cancer, has become a UK government-accredited...

OXFORD, United Kingdom, Oct. 15, 2024 -- Optellum, a leading innovator in artificial intelligence (AI) and medical imaging for lung cancer, has secured joint...

OXFORD, United Kingdom, Aug. 9, 2024 /PRNewswire/ -- Optellum, a global leader in AI-powered early lung disease diagnosis & precision care, today announced it has successfully achieved...

Lung cancer is a devastating disease for all involved. But there is hope. Early diagnosis enables doctors to undertake the early surgical intervention needed...

    A new whitepaper released with Georgia Cancer Center shows how Optellum's Virtual Nodule Clinic (VNC) has helped transform their management of incidentally detected lung nodules. This innovative...